targeting acute and chronic inflammation. Our primary focus is on the development of monoclonal antibodies that target activation products of the complement system for application in life-threatening inflammatory diseases. We are a team of internationally recognized researchers and clinicians who have dedicated our careers to translating discoveries and expertise into new therapeutic concepts for clinical application.
C5a is a key player in many acute and chronic inflammatory processes. Thus, C5a is a highly attractive pharmacological target. However, a special Technology is required to effectively control this target.
InflaRx develops highly specific monoclonal antibodies targeting activation products of the complement system. InflaRx has made breakthrough discoveries in the area of anti-C5a antibody generation, resulting in a new class of highly selective antibodies with exceptional blocking activities.
InflaRx focuses on diseases with high unmet medical need. Vilobelimab, the company's first-in-class anti-human C5a monoclonal antibody is currently being developed in several chronic inflammatory diseases, as well as oncology and COVID-19-induced pneumonia.
The latest information on InflaRx share price with interactive charts, comparative analysis, historic figures and latest trade price is available here.
COVID-19 (BEAT-COV) in Germany to speed up development of COVID-19 therapies. More information (in German only) about the initiative, founded by four German biotech companies, click here…
InflaRx is founding member of the Biotech Emergency Alliance for Therapies against
Our lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical phase II development. read more ...
IFX-2 is a follow-on project to vilobelimab, in preclinical development. IFX-2 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered pharmacokinetic properties. read more ...
Jena, Germany, March 22, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical comp...
Jena, Germany, January 5, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical com...
Jena, Germany, December 21, 2022 – InflaRx N.V. (Nasdaq: IFRX) (the “Company” or “InflaRx”), a clini...
Jena, Germany, November 9, 2022 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical co...
Jena, Germany, November 9, 2022 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical co...
Jena, Germany, September 29, 2022 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical ...
Jena, Germany, September 9, 2022 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical c...
Jena, Germany, September 08, 2022 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical ...
Jena, Germany, August 5, 2022 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharma-ceutical com...
Jena, Germany, July 26, 2022 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical compa...
